Atlas Genetics Raises $35M in Series D Funding

Atlas Genetics, a UK-based company specializing in ultra-rapid Point-Of-Care (POC) molecular diagnostics, has secured $35 million in Series D funding. The round was led by existing investors Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners, and new investor Wondfo Biotech, a Chinese in vitro diagnostic company. The company plans to use the funds to finance clinical trials and commercial launch of a second test for detection of both Chlamydia and Gonorrhoea, further develop its diagnostics menu, and expand cartridge manufacturing capacity.

Atlas Genetics Raises $35 Million in Series D Funding to Expand Molecular Diagnostics

Atlas Genetics is a UK-based ultra-rapid Point-Of-Care (POC) molecular diagnostics company that develops ultra-rapid POC diagnostic tests for infectious diseases. Its io® system is a novel molecular diagnostic platform for the ultra-rapid diagnosis of a broad range of infectious diseases based on a patent-protected electrochemical sensor technology. An integrated cartridge, which contains all reagents, is designed to receive an unprocessed clinical specimen. Each cartridge can detect up to 24 different genetic targets from a patient sample.

Atlas Genetics develops ultra-rapid Point-Of-Care (POC) molecular diagnostics tests for infectious diseases.

9 years ago

Atlas Genetics Raises $35 Million in Series D Funding to Expand Molecular Diagnostics

ProblemHealthcare

Solution

Covered on